Research ExplorerPublicationsWhere Do We Look for Markers of Radiotherapy Fraction Size S...

Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity?

Standard

Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity? / Somaiah, N; Rothkamm, K; Yarnold, J.

In: CLIN ONCOL-UK, Vol. 27, No. 10, 21.06.2015, p. 570-578.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Somaiah, N, Rothkamm, K & Yarnold, J 2015, 'Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity?', CLIN ONCOL-UK, vol. 27, no. 10, pp. 570-578. https://doi.org/10.1016/j.clon.2015.06.006

APA

Somaiah, N., Rothkamm, K., & Yarnold, J. (2015). Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity? CLIN ONCOL-UK, 27(10), 570-578. https://doi.org/10.1016/j.clon.2015.06.006

Vancouver

Somaiah N, Rothkamm K, Yarnold J. Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity? CLIN ONCOL-UK. 2015 Jun 21;27(10):570-578. https://doi.org/10.1016/j.clon.2015.06.006

Bibtex

@article{c53b161c196c49c6b56cd2b68b80ef69,
title = "Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity?",
abstract = "The response of human normal tissues to radiotherapy fraction size is often described in terms of cellular recovery, but the causal links between cellular and tissue responses to ionising radiation are not necessarily straightforward. This article reviews the evidence for a cellular basis to clinical fractionation sensitivity in normal tissues and discusses the significance of a long-established inverse association between fractionation sensitivity and proliferative indices. Molecular mechanisms of fractionation sensitivity involving DNA damage repair and cell cycle control are proposed that will probably require modification before being applicable to human cancer. The article concludes by discussing the kind of correlative research needed to test for and validate predictive biomarkers of tumour fractionation sensitivity.",
author = "N Somaiah and K Rothkamm and J Yarnold",
note = "Copyright {\textcopyright} 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.",
year = "2015",
month = jun,
day = "21",
doi = "10.1016/j.clon.2015.06.006",
language = "English",
volume = "27",
pages = "570--578",
journal = "CLIN ONCOL-UK",
issn = "0936-6555",
publisher = "W.B. Saunders Ltd",
number = "10",

}

RIS

TY - JOUR

T1 - Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity?

AU - Somaiah, N

AU - Rothkamm, K

AU - Yarnold, J

N1 - Copyright © 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

PY - 2015/6/21

Y1 - 2015/6/21

N2 - The response of human normal tissues to radiotherapy fraction size is often described in terms of cellular recovery, but the causal links between cellular and tissue responses to ionising radiation are not necessarily straightforward. This article reviews the evidence for a cellular basis to clinical fractionation sensitivity in normal tissues and discusses the significance of a long-established inverse association between fractionation sensitivity and proliferative indices. Molecular mechanisms of fractionation sensitivity involving DNA damage repair and cell cycle control are proposed that will probably require modification before being applicable to human cancer. The article concludes by discussing the kind of correlative research needed to test for and validate predictive biomarkers of tumour fractionation sensitivity.

AB - The response of human normal tissues to radiotherapy fraction size is often described in terms of cellular recovery, but the causal links between cellular and tissue responses to ionising radiation are not necessarily straightforward. This article reviews the evidence for a cellular basis to clinical fractionation sensitivity in normal tissues and discusses the significance of a long-established inverse association between fractionation sensitivity and proliferative indices. Molecular mechanisms of fractionation sensitivity involving DNA damage repair and cell cycle control are proposed that will probably require modification before being applicable to human cancer. The article concludes by discussing the kind of correlative research needed to test for and validate predictive biomarkers of tumour fractionation sensitivity.

U2 - 10.1016/j.clon.2015.06.006

DO - 10.1016/j.clon.2015.06.006

M3 - SCORING: Journal article

C2 - 26108884

VL - 27

SP - 570

EP - 578

JO - CLIN ONCOL-UK

JF - CLIN ONCOL-UK

SN - 0936-6555

IS - 10

ER -